Table 1.
Baseline characteristics
| Total (n = 167) | NCA (n = 56) | sCAD (n = 53) | AMI (n = 58) | P value | |
|---|---|---|---|---|---|
| Demographic characteristics | |||||
| Age | 57.76 ± 11.80 | 54.23 ± 12.5 | 58.30 ± 11.41 | 60.67 ± 10.73 | 0.012 |
| Gender/Male (%, M) | 125 (74.9%) | 35 (62.5%) | 40 (75.5%) | 50 (86.2%) | 0.014 |
| Clinical characteristics | |||||
| BMI, kg/m2 | 25.18 ± 3.19 | 25.22 ± 2.70 | 25.01 ± 3.05 | 25.30 ± 3.76 | 0.889 |
| Smoking (%, Y) | 95 (56.9%) | 17 (30.4%) | 34 (64.2%) | 44 (75.9%) | < 0.0001 |
| Drinking (%, Y) | 72 (43.1%) | 15 (26.8%) | 31 (58.5%) | 26 (44.8%) | 0.004 |
| Diabetes mellitus (%, Y) | 46 (27.5%) | 4 (7.1%) | 21 (39.6%) | 21 (36.2%) | < 0.0001 |
| Hyperlipemia (%, Y) | 101 (60.5%) | 20 (35.7%) | 41 (77.4%) | 40 (69.0%) | < 0.0001 |
| Laboratory characteristics | |||||
| Hemoglobin, g/L | 134.68 ± 18.37 | 142.31 ± 16.84 | 134.26 ± 19.38 | 127.68 ± 16.11 | < 0.0001 |
| FBG, mmol/L | 6.58 ± 2.61 | 5.35 ± 1.04 | 7.04 ± 2.60 | 7.34 ± 3.21 | < 0.0001 |
| HbA1c, % | 6.30 ± 1.29 | 5.91 ± 0.87 | 6.55 ± 1.51 | 6.44 ± 1.34 | 0.019 |
| Scr, μmol/L | 83.59 ± 17.90 | 75.72 ± 16.22 | 87.21 ± 18.87 | 87.87 ± 16.23 | < 0.0001 |
| Uric acid, μmol/L | 331.47 ± 86.72 | 324.13 ± 79.45 | 356.62 ± 86.68 | 315.58 ± 89.76 | 0.032 |
| LDH, IU/L | 276.64 ± 237.57 | 171.68 ± 37.18 | 188.83 ± 44.50 | 458.24 ± 331.19 | < 0.0001 |
| hsCRP, mg/L | 3.86 ± 5.12 | 1.94 ± 2.41 | 2.78 ± 3.57 | 6.69 ± 6.81 | < 0.0001 |
| ALT, IU/L | 35.04 ± 32.59 | 30.09 ± 30.37 | 35.64 ± 38.92 | 39.28 ± 27.91 | 0.320 |
| AST, IU/L | 55.25 ± 80.02 | 23.29 ± 13.74 | 25.998 ± 16.53 | 112.95 ± 114.11 | < 0.0001 |
| HDL-C, mmol/L | 1.22 ± 1.15 | 1.19 ± 0.31 | 1.10 ± 0.35 | 1.36 ± 1.90 | 0.482 |
| LDL-C, mmol/L | 2.56 ± 0.97 | 2.79 ± 0.87 | 2.48 ± 1.09 | 2.42 ± 0.91 | 0.093 |
| TC, mmol/L | 4.29 ± 1.16 | 4.62 ± 0.92 | 4.07 ± 1.37 | 4.17 ± 1.09 | 0.029 |
| TG, mmol/L | 2.12 ± 5.98 | 1.83 ± 1.19 | 1.76 ± 0.88 | 2.73 ± 10.08 | 0.635 |
| NT-proBNP, pg/mL | 496.40 ± 1504.93 | 86.25 ± 221.68 | 224.41 ± 396.73 | 1140.94 ± 2397.50 | < 0.0001 |
| CK, IU/L | 372.70 ± 659.52 | 99.80 ± 57.03 | 118.38 ± 134.82 | 868.59 ± 929.25 | < 0.0001 |
| cTnI, ng/mL | 8.64 ± 20.38 | 0.15 ± 0.30 | 0.89 ± 2.94 | 23.92 ± 28.94 | < 0.0001 |
| MYO, ng/mL | 256.08 ± 572.39 | 28.26 ± 11.63 | 48.63 ± 47.83 | 665.59 ± 830.84 | < 0.0001 |
| CK-MB, ng/mL | 34.05 ± 65.07 | 3.42 ± 4.95 | 7.06 ± 21.94 | 88.30 ± 85.29 | < 0.0001 |
Data are means ± SD or number (percentage) of subjects. BMI body mass index, FBG fasting blood glucose, HbA1c hemoglobin A1c, Scr serum creatinine, LDH lactate dehydrogenase, hsCRP hypersensitive C-reactive protein, ALT alanine aminotransferase, AST aspartate transaminase, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides, NT-proBNP N-terminal pro-brain natriuretic peptide, CK creatine kinase, cTnI cardiac troponin I, MYO myoglobin, CK-MB MB isoenzyme of creatine kinase, NCA normal coronary artery, sCAD stable coronary artery disease, AMI acute myocardial infarction. The chi-squared test was used for comparison of categorical variables and one-way analysis of variance (one-way ANOVA) was used for continuous variables. The P value<0.05 was regarded as statistically significant